A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
08/2011
08/18/2011	WO2011100468A2 Methods and materials for treating cancer
08/18/2011	WO2011100460A2 Ccr7 ligand delivery and co-delivery in immunotherapy
08/18/2011	WO2011100380A1 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
08/18/2011	WO2011100325A2 Polymorphs of sunitinib salts
08/18/2011	WO2011100319A1 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
08/18/2011	WO2011100295A2 Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
08/18/2011	WO2011100285A1 Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
08/18/2011	WO2011100282A2 Imatinib mesylate polymorphs
08/18/2011	WO2011100090A1 Methods of synthesizing and isolating n-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
08/18/2011	WO2011099980A1 Use of the lactosylceramide synthase isoform b1, 4galt-v as a biomarker for cancer
08/18/2011	WO2011099947A1 A new class of highly apoptotic anti-cancer agents
08/18/2011	WO2011099942A1 New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
08/18/2011	WO2011099882A1 Vaccine compositions and methods of use thereof
08/18/2011	WO2011099881A1 Pharmaceutical compositions containing antibodies to neuropeptide head activator and methods thereof
08/18/2011	WO2011099764A2 Novel pyrimidine derivative for inhibiting the growth of cancer cells
08/18/2011	WO2011099684A1 Single domain antibody against muc1
08/18/2011	WO2011099602A1 Porphyrin derivative and use thereof in radiation induced photodynamic therapy
08/18/2011	WO2011099576A1 Aptamer to fgf2 and use thereof
08/18/2011	WO2011099524A1 Radioactive metal-labeled anti-cadherin antibody
08/18/2011	WO2011099507A1 Salt of fused heterocyclic derivative and crystal thereof
08/18/2011	WO2011099502A1 Use of compound binding to msin3b that specifically binds to neuron restrictive silencer factor (nrsf)
08/18/2011	WO2011099039A1 Process for the preparation of alpha form of imatinib mesylate
08/18/2011	WO2011099007A1 Pharmaceutical compositions and methods for the treatment and prevention of cancer
08/18/2011	WO2011098971A1 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
08/18/2011	WO2011098611A2 Alpha-emitting complexes
08/18/2011	WO2011098610A1 Carbonic anhydrase inhibitors
08/18/2011	WO2011098607A1 Salts and hydrates of 4-[(3-chlor-4-fluoro-phenyl)amino]-6-(cis-4-{n-[(morph-1-olino-4-yl)carbonyl]-n-methyl-amino}-cyclohexane-1-yloxy)-7-methoxy-quinazoline, their use as drugs and their production
08/18/2011	WO2011098603A1 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors
08/18/2011	WO2011098452A1 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
08/18/2011	WO2011098451A1 Purine derivatives and their pharmaceutical uses
08/18/2011	WO2011098433A1 Cyclic keto-enols for therapy
08/18/2011	WO2011098398A1 Substituted pyrrolidine-2-carboxamides
08/18/2011	WO2011097797A1 Polyphenol acrylic acid derivative, preparation and use in preparing medicine thereof
08/18/2011	WO2011097750A1 Compositions, products, therapeutic uses and procedures for the production and/or crystallisation of extracts of encelia canescens lam (coronilla de fraile)
08/18/2011	WO2011097712A1 Hybrid molecule having mixed retinoic acid receptor agonism and histone deacetylase inhibitory properties
08/18/2011	WO2011082267A8 Substituted triazolo-pyrazine compounds
08/18/2011	WO2011079249A3 Vitamin d glycosides and sulfates for treating diseases
08/18/2011	WO2011077043A3 Phenol derivatives and pharmaceutical or cosmetic use thereof
08/18/2011	WO2011069795A4 Neutralizing prolactin receptor antibodies and their therapeutic use
08/18/2011	WO2011057220A9 Compositions and methods for treating lymphoma
08/18/2011	WO2011049960A9 Compositions and methods for the treatment of sinonasal disorders
08/18/2011	WO2011049810A3 Compositions and methods for treating inflammation and fibrosis
08/18/2011	WO2011047277A3 Release of agents from cells
08/18/2011	WO2011047269A3 Elongator proteins and use thereof as dna demethylases
08/18/2011	WO2011047055A3 Novel mek inhibitors, useful in the treatment of diseases
08/18/2011	WO2011047051A3 Polymeric systems for the delivery of anticancer agents
08/18/2011	WO2011046991A3 Certain substituted ureas as modulators of kinase activity
08/18/2011	WO2011046832A3 Granulysin in immunotherapy
08/18/2011	WO2011041694A3 Compounds as lysophosphatidic acid receptor antagonists
08/18/2011	WO2011041399A3 Pi3k (delta) selective inhibitors
08/18/2011	WO2011040954A9 Tp53 gene expression and uses thereof
08/18/2011	WO2011038142A3 Bladder cancer specific ligand peptides
08/18/2011	WO2011029008A3 Synbodies to akt1
08/18/2011	WO2011027980A3 Tumor cell-killing peptides
08/18/2011	WO2011023367A3 Bisphosphonate-prodrugs
08/18/2011	WO2011020879A3 Use of an extract obtained from plants of the sub-family rutoideae in the treatment of cancer
08/18/2011	WO2011019636A3 Methods and compositions for the treatment of cancers and pathogenic infections
08/18/2011	WO2010068181A8 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
08/18/2011	US20110201678 Xanthenone-4-Acetic Acid Derivatives
08/18/2011	US20110201677 Promoters exhibiting endothelial cell specificity and methods of using same
08/18/2011	US20110201675 ON01910.Na ENHANCES CHEMOTHERAPEUTIC AGENT ACTIVITY IN DRUG-RESISTANT TUMORS
08/18/2011	US20110201669 Methods and compositions for the diagnosis and treatment of cancer
08/18/2011	US20110201664 Methods and Compositions for Treatment of Prostate Intraepithelial Neoplasia
08/18/2011	US20110201661 Spiro Derivatives of Parthenin as Novel Anticancer Agents
08/18/2011	US20110201657 Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
08/18/2011	US20110201655 Pharmaceutical composition improving intestinal absorption
08/18/2011	US20110201653 Method for inhibiting and/or preventing formation of cancer metastases and secondary malignant cancer
08/18/2011	US20110201648 Poly-heteroaryl derivatives for the treatment of cancer
08/18/2011	US20110201647 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
08/18/2011	US20110201643 Novel n-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
08/18/2011	US20110201642 Bioactive Compounds
08/18/2011	US20110201641 Indole derivatives as crth2 receptor antagonists
08/18/2011	US20110201640 Tricyclic compound
08/18/2011	US20110201638 PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
08/18/2011	US20110201637 Phenanthroindolizidine derivative and nfkb inhibitor containing same as active ingredient
08/18/2011	US20110201635 Substituted spiroindolinones
08/18/2011	US20110201633 Alfuzosin tablets and synthesis
08/18/2011	US20110201631 Pharmaceutical formulations comprising pemetrexed
08/18/2011	US20110201628 Heterocyclic jak kinase inhibitors
08/18/2011	US20110201620 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
08/18/2011	US20110201619 Use of N-Phenyl-2-pyrimidineamine Derivatives Against Mast Cell-based Diseases Like Allergic Disorders
08/18/2011	US20110201612 Compositions for Modulating a Kinase Cascade and Methods of Use Thereof
08/18/2011	US20110201611 Process for the Preparation of Compositions for Modulating a Kinase Cascade and Methods of Use Thereof
08/18/2011	US20110201609 Proteasome inhibitors for selectively inducing apoptosis in cancer cells
08/18/2011	US20110201608 Substituted naphthyridines and use thereof as medicines
08/18/2011	US20110201606 Pyrimidine derivatives
08/18/2011	US20110201604 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
08/18/2011	US20110201602 Protein kinase modulators and method of use
08/18/2011	US20110201600 Chalcone linked pyrrolo[2,1-c][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
08/18/2011	US20110201599 CDK Modulators
08/18/2011	US20110201598 Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer
08/18/2011	US20110201594 Pyrido [2,3-d] pyrimidines and their use as kinase inhibitors
08/18/2011	US20110201592 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use
08/18/2011	US20110201584 Certain chemical entities, compositions, and methods
08/18/2011	US20110201576 Small molecule inhibitors of stat3 with anti-tumor activity
08/18/2011	US20110201563 Chimeric small molecules for the recruitment of antibodies to cancer cells
08/18/2011	US20110201561 Treatment of metastatic colon cancer with b-subunit of shiga toxin
08/18/2011	US20110201560 Peptides for inhibiting the hpv-e6 oncoprotein
08/18/2011	US20110201559 New Optically Pure Compounds for Improved Therapeutic Efficiency
08/18/2011	US20110201555 Novel estrogen receptor ligands

1 ... 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 ... 2211